Increase of proliferation rate and enhancement of antitumor cytotoxicity of expanded human CD3+CD56+ immunologic effector cells by receptor-mediated transfection with the interleukin-7 gene

Gene Therapy

Volumn 5, Issue 1, 1998, Pages 31-39

  Finke, S ^a,b   Trojaneck, B ^a   Lefterova, P ^a   Csipai, M ^a   Wagner, E ^c   Kircheis, R ^c   Neubauer, A ^d   Huhn, D ^a   Wittig, B ^b   Schmidt Wolf, I G H ^a,e  

^a HUMBOLDT UNIVERSITY   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c BOEHRINGER INGELHEIM RCV GMBH AND CO KG   (Austria)

^d UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

CIK cells; Interleukin 7; NK cells; Receptor mediated gene transfer; T cells

Indexed keywords

CD3 ANTIGEN; CD56 ANTIGEN; COMPLEMENTARY DNA; CYTOKINE; INTERLEUKIN 7; TUMOR NECROSIS FACTOR ALPHA;

ADENOVIRUS; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOASSAY; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS; CYTOTOXICITY; DNA TRANSFECTION; EFFECTOR CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPRESSION VECTOR; GENE TRANSFER; HUMAN; HUMAN CELL; PLASMID; PRIORITY JOURNAL; PROMOTER REGION; RECOMBINANT GENE; TUMOR CELL LINE;

ADENOVIRIDAE; CUCUMBER MOSAIC VIRUS; CYTOMEGALOVIRUS;

EID: 6844240228     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300560     Document Type: Article

References (32)

1. + killer cells. Blood 1995; 86: 3493-3499.
2. Schmidt-Wolf IGH et al. Propagation of large numbers of T cells with natural killer cell markers Br J Haematol 1994; 87: 453-458.
3. + cells derived from T cells with potent in vivo antitumor activity in SCID mice. J Immunol 1994; 153: 1687-1696.
4. Namen AE et al. Stimulation of B cell progenitors by cloned murine IL-7. Nature 1993; 333: 571-573.
5. Goodwin RG et al. Human interleukin-7: molecular cloning and growth factor activity on human and murine B lineage cells. Proc Natl Acad Sci USA 1989; 86: 302-306.
6. Chazen GD et al. Interleukin-7 is a T cell growth factor. Proc Natl Acad Sci USA 1989; 86: 5923-5927.
7. Hickman CJ, Crim JA, Mostowski HS, Siegel JP. Regulation of human cytotoxic T lymphocyte development by IL-7. J Immunol 1990; 145: 2415-2420.
8. Welch PA et al. Human IL-7: a novel T cell growth factor. J Immunol 1989; 143: 3562-3567
9. Lotze MT et al. Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T cell growth factor. Cancer Res 1981; 41: 4420-4425.
10. Armitage RJ, Namen AE, Sassenfeld HM, Grabstein KH. Regulation of human T cell proliferation by IL-7. J Immunol 1990; 144: 938-941.
11. Jicha DL, Mule JJ, Rosenberg S. Interleukin-7 generates antitumor cytotoxic T lymphocytes against murine sarcomas with efficacy in cellular adoptive immunotherapy. J Exp Med 1990; 174: 1511-1515.
12. Csipai M et al. Effects of interleukin-7 on proliferation of tumor cells. Cancer Res Ther Contr 1996; 5: 11-16.
13. Lynch DH, Miller RE. Induction of murine lymphokine-activated killer cells by recombinant IL-7. J Immunol 1990; 145: 1983-1990.
14. Alderson MR, Sassenfeld HM, Widmer MB. Interleukin-7 enhances cytolytic T lymphocyte generation and induces lymphokine activated killer cells from human peripheral blood. J Exp Med 1990; 172: 577-587
15. Lynch DH, Namen AE, Miller RE. In vivo evaluation of the effects of interleukins 2, 4 and 7 on enhancing the immunotherapeutic efficacy of anti-tumor cytotoxic T lymphocytes. Eur J Immunol 1991; 21: 2977-2985.
16. Naume B, Espevik T. Effects of IL-7 and IL-2 on highly enriched CD56- natural killer cells. J Immunol 1991; 147: 2208-2214.
17. Schmidt-Wolf G, Schmidt-Wolf IGH. Cytokines and clinical gene therapy. Eur J Immunol 1995; 25: 1137-1140.
18. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine activated killer cell phenomenon: lysis of natural killer resistant fresh solid tumor cells by IL-2 activated autologous human peripheral blood Iymphocytes. J Exp Med 1982; 155: 1823-1841.
19. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor infiltrating lymphocytes. Science 1986; 233: 1318-1321.
20. + killer cells. Ann Hematol 1997; 74: 51-56.
21. Rosenberg SA, Aebersold P, Cornetta K. Gene transfer into humans - immunotherapy of patients with advanced melanoma, using tumor infiltrating lymphocytes modified by retroviral gene transduction. New Engl J Med 1990; 323: 570-578.
22. + T cell dependent tumor rejection. J Exp Med 1991; 174: 1291-1298.
23. Schmidt-Wolf IGH et al. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 1991; 174: 139-149.
24. Stötter H et al. IL-7 induces lymphokine-activated killer cell activity and is regulated by IL-4. J Immunol 1990; 146: 150-155.
25. Ebert O et al. Lymphocyte apoptosis. induction by gene transfer techniques. Gene Therapy 1997; 4: 296-302.
26. Schmidt-Wolf GD, Schmidt-Wolf IGH. Cancer and gene therapy. Ann Hematol 1996; 73: 207-218.
27. Buschle M et al. Receptor-mediated gene transfer into human T lymphocytes via binding of DNA/CD3 antibody particles to the CD3 T cell receptor complex. Hum Gene Ther 1995; 6: 753-761.
28. Schmidt-Wolf G, Schmidt-Wolf IGH. Cytokines and gene therapy. Immunol Today 1995; 16: 173-175.
29. Hwu P et al. Functional and molecular characterization of tumor-infiltrating lymphocytes transduced with tumor necrosis factor alpha cDNA for the gene therapy of cancer in humans. J Immunol 1993; 150: 4104-4115.
30. Nakamura Y et al. Adoptive immunotherapy with murine tumor-specific T lymphocytes engineered to secrete interleukin-2. Cancer Res 1994; 54: 5757-5760.
31. McBride WH et al. Genetic modification of a murine fibrosarcoma to produce interleukin 7 stimulates host cell infiltration and tumor immunity. Cancer Res 1992; 52: 3931-3937.
32. Gotten M, Wagner E. Nonviral approaches to gene therapy Curr Opin Biotech 1993; 4: 705-710.